Altor BioScience Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
60
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1B
Altor BioScience General Information
Description
Developer of novel immunotherapies designed to treat cancer and viral infections. The company's immunotherapies focus on the immunostimulatory properties of the cytokines IL-15 and IL-2, offer links between the innate and adaptive arms of the immune system and induce the activation, proliferation and persistence of NK and T cells that are critical in the body's defense against cancer and infection, enabling HIV infected individuals and patients with hematological tumors to regulate the function of the immune system.
Contact Information
Website
www.altorbioscience.comCorporate Office
- 2810 North Commerce Parkway
- Miramar, FL 33025
- United States
Corporate Office
- 2810 North Commerce Parkway
- Miramar, FL 33025
- United States
Altor BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 01-Aug-2017 | $1B | Completed | Generating Revenue | ||
| 12. Later Stage VC (Series H) | 22-Mar-2017 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series G) | 19-Jul-2016 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 01-Jan-2016 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Private | 01-Jan-2016 | Completed | Generating Revenue | |||
| 8. Grant | 06-Oct-2015 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series F) | 01-Jun-2015 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series E) | 14-Mar-2013 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 20-Jul-2012 | $11.3M | $37.1M | Completed | Generating Revenue | |
| 4. Later Stage VC | 26-Jul-2010 | $1.63M | $25.8M | Completed | Generating Revenue |
Altor BioScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series H | ||||||||
| Series G | ||||||||
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C1 | ||||||||
| Series B1 | ||||||||
| Series A2 | 2,775,567 | $0.001000 | $0.02 | $0.56 | $0.56 | 1x | $0.56 | 1.99% |
| Series A1 | 4,465,507 | $0.001000 | $0.02 | $0.44 | $0.44 | 1x | $0.44 | 3.2% |
Altor BioScience Comparisons
Industry
Financing
Details
Altor BioScience Competitors (71)
One of Altor BioScience’s 71 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Noveome Biotherapeutics | Venture Capital-Backed | Pittsburgh, PA | ||||
| Gylden Pharma | Venture Capital-Backed | Abingdon, United Kingdom | ||||
| Equillium | Formerly VC-backed | La Jolla, CA |
Altor BioScience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Altor BioScience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Altor BioScience Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gates Foundation | Not-For-Profit Venture Capital | |||
| Hamilton Lane Advisors | Asset Manager | Minority | ||
| JSD Capital | Growth/Expansion | Minority | ||
| National Cancer Institute | Government | |||
| National Heart, Lung, and Blood Institute | Government |
Altor BioScience Acquisitions (1)
Altor BioScience’s most recent deal was a Merger/Acquisition with Sunol Molecular. The deal was made on 25-Mar-2005.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sunol Molecular | 25-Mar-2005 | Merger/Acquisition | Drug Discovery |
Altor BioScience FAQs
-
When was Altor BioScience founded?
Altor BioScience was founded in 2002.
-
Where is Altor BioScience headquartered?
Altor BioScience is headquartered in Miramar, FL.
-
What is the size of Altor BioScience?
Altor BioScience has 60 total employees.
-
What industry is Altor BioScience in?
Altor BioScience’s primary industry is Drug Discovery.
-
Is Altor BioScience a private or public company?
Altor BioScience is a Private company.
-
What is the current valuation of Altor BioScience?
The current valuation of Altor BioScience is .
-
What is Altor BioScience’s current revenue?
The current revenue for Altor BioScience is .
-
How much funding has Altor BioScience raised over time?
Altor BioScience has raised $119M.
-
Who are Altor BioScience’s investors?
Gates Foundation, Hamilton Lane Advisors, JSD Capital, National Cancer Institute, and National Heart, Lung, and Blood Institute are 5 of 11 investors who have invested in Altor BioScience.
-
Who are Altor BioScience’s competitors?
Marengo Therapeutics, Kite Pharma, Noveome Biotherapeutics, Gylden Pharma, and Equillium are some of the 71 competitors of Altor BioScience.
-
When was Altor BioScience acquired?
Altor BioScience was acquired on 01-Aug-2017.
-
Who acquired Altor BioScience?
Altor BioScience was acquired by ImmunityBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
